The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 4.05 — safe zoneOK
- Earnings-manipulation signal · Beneish M -1.44 — flag raised, worth a closer lookWatch
- Earnings quality 100/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as TransMedics Group, Inc. reports it. History and quarterly detail are in the app.
- Liver Product$459.4M
- Product$372.4M
- Service$233.1M
- Heart Product$111.8M
- Lung Product$13.4M
Leadership changes
From TransMedics Group, Inc.'s own filings, the day they're filed.
- Giovanni Cecere · Chief Commercial Officer · appointmenteff. 2026-02-02
- Tamer Khayal · Chief Commercial Officer · appointmenteff. 2026-02-02
- Matthew Forsyth · President · appointmenteff. 2026-02-02
Latest filings
- 8-K · Company announcement2026-08-04
- 10-Q · Quarterly report2026-08-04
- 8-K · Company announcement2026-05-21
- 8-K · Company announcement2026-05-05
- 10-Q · Quarterly report2026-05-05
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about TransMedics Group, Inc., every answer cited to the official filings🔒
- The Intelligence Brief — added when TransMedics Group, Inc.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.